⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AKTX News
Akari Therapeutics plc ADR (0.01 USD)
Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity
globenewswire.com
AKTX
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
globenewswire.com
AKTX
Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board
globenewswire.com
AKTX
Form 8-K
sec.gov
AKTX
Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones
globenewswire.com
AKTX
Form 8-K
sec.gov
AKTX
Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari’s Differentiated PH1 Payload Platform Following ASCO 2026
globenewswire.com
AKTX
Akari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor “What This Means” Segment Following ASCO Abstract Acceptance
globenewswire.com
AKTX
Form 8-K
sec.gov
AKTX
This Emerging Biotech Wave Could Create the Next Monster Healthcare Winners
globenewswire.com
AKTX
NTHI
MTVA
HCWB